Avid Bioservices to Exhibit at The Bioprocessing Summit 2017
August 16 2017 - 8:05AM
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine
Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced
that the company will exhibit at the upcoming Bioprocessing Summit
2017, being held August 21-25, 2017 in Boston, MA. Avid will
host a corporate booth (#403) in the conference’s exhibit hall,
where it will showcase the company’s comprehensive range of process
development, high quality cGMP clinical and commercial
manufacturing services for the biotechnology and biopharmaceutical
industries.
At the Bioprocessing Summit 2017, the Avid team
will be able to discuss the company’s innovative processes for
generating a broad range of biopharmaceutical product types
including monoclonal antibodies, highly-glycosylated recombinant
proteins and enzymes, among others.
As part of its exhibit, Avid will provide a
virtual tour of the company’s 42,000 square foot state-of-the-art
Myford manufacturing facility, which is designated for late-stage
clinical and commercial manufacturing. As previously announced, the
company will soon be ready to offer new larger scale capacity from
the two recently installed 2,000-liter, single-use bioreactors at
the Myford facility. The Myford facility is designed with
cutting-edge, single-use equipment to accommodate a fully
disposable biomanufacturing process. A wide range of
innovative features are incorporated into the new Myford facility
including monolithic modular clean rooms, dedicated support
utilities for each key processing area, and the industry’s most
advanced single-use production systems and flexible
solutions. Uni-directional process flows separate personnel
and materials and provide assurance that the design meets the most
stringent regulatory requirements for commercial biologics API
manufacturing.
For more information on The Bioprocessing Summit
2017, please visit: http://www.bioprocessingsummit.com/
About Avid Bioservices, Inc.Avid Bioservices, a
wholly owned subsidiary of Peregrine Pharmaceuticals, provides a
comprehensive range of process development, high quality cGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 20 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, Avid's services
include cGMP clinical and commercial product manufacturing,
purification, bulk packaging, stability testing and regulatory
strategy, submission and support. The company also provides a
variety of process development activities, including cell line
development and optimization, cell culture and feed optimization,
analytical methods development and product characterization. For
more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering
high quality pharmaceutical products through its contract
development and manufacturing organization (CDMO) services and
through advancing and licensing its investigational immunotherapy
and related products. Peregrine's in-house CDMO services,
including cGMP manufacturing and development capabilities, are
provided through its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. The
company is also working to evaluate its lead immunotherapy
candidate, bavituximab, in combination with immune stimulating
therapies for the treatment of various cancers, and developing its
proprietary exosome technology for the detection and monitoring of
cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024